UTHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
United Therapeutics Corp (UTHR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, upcoming product launches, and positive analyst sentiment support this recommendation. The technical indicators also suggest a bullish trend, making this a suitable entry point.
The stock is showing bullish momentum with MACD positively expanding, RSI in the neutral zone at 59.037, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). The pre-market price is $511.54, up 1.58%, with a key support level at 468.83 and resistance at 523.22.
Strong Q4 earnings with EPS growth of 23.99% YoY and net income growth of 20.91% YoY.
Positive analyst sentiment with multiple price target upgrades, including RBC Capital raising its target to $
Upcoming launches of innovative products like the soft mist inhaler (Tresmi) and Phase 3 readouts for Tyvaso and Ralinepag, which have a high probability of success.
Management's goal of achieving a $4B revenue run rate by 2H27.
Q4 revenue missed expectations, leading to a temporary drop in shares.
Gross margin declined by 3.10% YoY, which may indicate cost pressures.
Neutral sentiment from hedge funds and insiders, with no significant trading trends.
In Q4 2025, United Therapeutics reported revenue growth of 7.38% YoY to $790.2 million, net income growth of 20.91% YoY to $364.3 million, and EPS growth of 23.99% YoY to $7.70. However, gross margin dropped by 3.10% YoY to 86.91%.
Analysts are overwhelmingly positive on the stock, with multiple price target upgrades ranging from $466 to $645. The consensus is that the company's innovative product pipeline and strategic initiatives position it well for long-term growth.
